After a lull in mid-2025, investment in UK biotechs appears to be picking up, according to data from the UK trade group the BioIndustry Association.
In the first quarter of 2026, total equity funding in …
A year after it reported a Phase 2/3 success, Compass Therapeutics on Monday revealed further results for its closely watched bispecific antibody in second-line biliary
A court ruling in the US has delivered a setback for GSK and its Tesaro subsidiary in their dispute with AnaptysBio over cancer drug Jemperli.
An experimental treatment that uses CRISPR to edit genes directly inside the body has just succeeded in a Phase 3 trial — a first for
Veradermics has succeeded in its first major test as a newly-minted public company. The biotech’s form of oral Rogaine cleared the bar in a Phase
In the early 2000s, way before AI became a ubiquitous buzzword in biotech, billionaire scientist David Shaw was building supercomputers to study molecules at his
After a lull in mid-2025, investment in UK biotechs appears to be picking up, according to data from the UK trade group the BioIndustry Association.
In the first quarter of 2026, total equity funding in …